CoStar Q3 2026 slides: EBITDA doubles as bookings disappoint

CoStar reported Q3 revenue of $952 million, up 14% year over year, and adjusted EPS of $0.38 versus $0.34 expected; record adjusted EBITDA was $229 million. However, annualized net new bookings fell to $37 million from $84 million a year earlier, and shares dropped 7.84% after hours to $29.32. CoStar raised 2026 revenue guidance to $3.75–$3.77 billion and adjusted EBITDA guidance to $820–$840 million, while management cited sales-force capacity and market conditions as bookings headwinds.

Analysis

The key issue is whether bookings weakness reflects temporarily inadequate sales coverage or a weaker willingness to buy. Those causes have very different implications: adding sales capacity can repair the former, but would not fix the latter—and could raise costs before revenue arrives. Until bookings and rep productivity improve, cost actions may support reported margins while masking weaker forward demand. There is also a quality-of-earnings caveat: stock-based compensation alone was about 22% of adjusted EBITDA, so the record adjusted result overstates the improvement visible in GAAP profitability and shareholder dilution remains relevant.

The Commercial business’s stronger profitability can cushion a slowdown, but Residential is the larger growth engine and its low segment margin makes sustained investment and acquisition integration important to the consolidated growth case. Zonda and the pending Vexcel deal add execution risk; savings that reduce product or sales capacity could undermine the very growth recovery management is underwriting. The prospective competitive spillover is an opening for alternatives such as Zillow Group to win residential customers if CoStar’s sales reach remains constrained, though the article provides no evidence of share shifts.

Near term, raised guidance and margin expansion may limit downside, but they do not resolve the bookings signal. Over the next 1–3 months, watch bookings, sales-force hiring/productivity, and Residential growth; the claimed 2027 sales-capacity recovery is a longer-dated thesis, not yet demonstrated. The 52% year-to-date decline makes chasing a fresh short unattractive. The contrarian opportunity is to become constructive only if bookings stabilize without sacrificing margins. A sustained bookings recovery alongside maintained guidance would falsify the bearish thesis; further bookings deterioration or a guidance cut would confirm it.

Key Decisions for Investors

• Do not buy CSGP solely on the earnings beat or raised guidance. Keep exposure underweight and avoid chasing the after-hours decline; consider adding downside exposure only on a relief rally if the next bookings update weakens and option pricing supports defined risk.
• Use the next quarter as a confirmation point: track net new bookings, sales-force additions and productivity, Residential revenue growth, and whether margin gains rely on continued cost reductions. Treat management’s 2027 capacity recovery as unproven until hiring and bookings data support it.
• Reassess the bearish view if bookings stabilize or recover while guidance and Residential growth hold. Escalate it if bookings fall again, management reduces growth guidance, or savings appear to constrain sales/product investment; those outcomes would weaken the case that margin expansion can bridge the growth gap.